Jeremy Grimshaw

Dr. Jeremy M. Grimshaw, MBChB, PhD, FRCGP, FCAHS is a Canadian health information specialist and epidemiologist based in Ottawa, Ontario.

Grimshaw is a Tier 1 Canada Research Chair in Health Knowledge Transfer and Uptake.¹⁾

• Faculty of Medicine, University of Edinburgh, 1979 - 1984
• Faculty of Medicine, University of Aberdeen, 1989 - 1997

Grimshaw is a fellow of the Canadian Academy of Health Sciences.²⁾

Grimshaw is a professor in the Department of Medicine at the University of Ottawa.³⁾

Grimshaw is the President of the Board of the Directors of the Campbell Collaboration.⁴⁾

He was initially elected as co-chair in 2016.⁵⁾

Grimshaw is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute.⁶⁾

Grimshaw

Grimshaw has been a presenter for AcademyHealth.⁷⁾

Grimshaw is a member of the Behavioural Science Working Group of the Ontario COVID-19 Science Advisory Table.⁸⁾

Grimshaw received a strategic grant from the Cardiac Arrhythmia Network of Canada for a study titled “Decreasing Hospital Admissions from the Emergency Department for Acute Atrial Fibrillation”.⁹⁾ CANC is partnered with many organizations with interest in COVID-19 including Apotex, Bayer, Boehringer Ingelheim, IBM, Johnson & Johnson, LifeLabs, Medtronic, Pfizer, and St. Jude Medical (an Abbott company).¹⁰⁾

Grimshaw is a co-Principal Investigator of the COVID-END study, funded by the Canadian Institutes of Health Research (CIHR).¹¹⁾ He is also a member of the Canadian secretariat.¹²⁾

Grimshaw received an operating grant as a co-Principal Investigator for a study called “An implementation science approach to increase attendance to retinopathy screening by people with diabetes.”¹³⁾

Grimshaw was recognized as a Thomson Reuters Highly Cited Researcher in 2015, 2016 2017 and 2018.^{14) 15)}